866-997-4948(US-Canada Toll Free)

Small-Cell Lung Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 200 Pages


Global Markets Directs, Small-Cell Lung Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Small-Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer. Small-Cell Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Small-Cell Lung Cancer.
  • A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Small-Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Small-Cell Lung Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Small-Cell Lung Cancer 9
Small-Cell Lung Cancer Therapeutics under Development by Companies 11
Small-Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Small-Cell Lung Cancer Therapeutics – Products under Development by Companies 20
Small-Cell Lung Cancer Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Small-Cell Lung Cancer Therapeutics Development 24
Bristol-Myers Squibb Company 24
Boehringer Ingelheim GmbH 25
Amgen Inc. 26
Sanofi-Aventis 27
Eli Lilly and Company 28
Merck & Co., Inc. 29
Dainippon Sumitomo Pharma Co., Ltd. 30
ZIOPHARM Oncology, Inc. 31
Millennium Pharmaceuticals, Inc. 32
ImmunoGen, Inc. 33
Nippon Kayaku Co., Ltd. 34
Menarini Group 35
Celgene Corporation 36
Onyx Pharmaceuticals, Inc. 37
Bayer AG 38
Alchemia Limited 39
Hana Biosciences, Inc. 40
ImmunoCellular Therapeutics, Ltd. 41
Critical Outcome Technologies Inc. 42
CytRx Corporation 43
Synta Pharmaceuticals Corp. 44
MabVax Therapeutics, Inc. 45
Supratek Pharma Inc. 46
TheRyte Ltd. 47
Celator Pharmaceuticals, Inc. 48
Cerulean Pharma, Inc. 49
OncoMed Pharmaceuticals, Inc. 50
Five Prime Therapeutics, Inc. 51
Merrimack Pharmaceuticals, Inc. 52
Neotropix, Inc. 53
MolMed S.p.A. 54
Innogene Kalbiotech Pte Ltd. 55
Laboratorios Farmaceuticos ROVI, S.A. 56
Mycenax Biotech Inc. 57
Polaris Group 58
CellAct Pharma GmbH 59
Small-Cell Lung Cancer – Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 67
ipilimumab - Drug Profile 67
lorvotuzumab mertansine - Drug Profile 70
irinotecan hydrochloride - Drug Profile 73
topotecan hydrochloride - Drug Profile 75
BMS-833923 - Drug Profile 77
amrubicin hydrochloride - Drug Profile 79
amrubicin hydrochloride - Drug Profile 81
NTX-010 - Drug Profile 83
ICT-109 - Drug Profile 85
FP-1039 - Drug Profile 87
NGR-hTNF - Drug Profile 89
COTI-2 - Drug Profile 92
ganetespib - Drug Profile 95
racotumomab - Drug Profile 99
irinotecan hydrochloride nanoliposomal - Drug Profile 100
topotecan hydrochloride - Drug Profile 102
palifosfamide tromethamine - Drug Profile 103
nintedanib - Drug Profile 105
CST-101 - Drug Profile 107
CRLX-101 - Drug Profile 108
TRBS-07 - Drug Profile 110
MDX-1110 - Drug Profile 111
ABT-737 - Drug Profile 112
pravastatin sodium + [carboplatin] + [etoposide] - Drug Profile 113
ADI-PEG 20 - Drug Profile 114
NK-012 - Drug Profile 117
temozolomide - Drug Profile 119
cabazitaxel - Drug Profile 120
Adva-27a - Drug Profile 121
COTI-219 - Drug Profile 123
COTI-4 - Drug Profile 124
COTI-58 - Drug Profile 125
(irinotecan hydrochloride + cisplatin) - Drug Profile 126
ardeparin sodium - Drug Profile 128
OMP-59R5 - Drug Profile 130
Drugs For Small Cell Lung Cancer - Drug Profile 132
5B1 - Drug Profile 133
Small Cell Lung Cancer Vaccine - Drug Profile 134
ZS-05 - Drug Profile 135
LY-2510924 - Drug Profile 136
Hibor - Drug Profile 137
CX-99 - Drug Profile 139
celecoxib - Drug Profile 140
CAP-7.1 - Drug Profile 141
EDC-7 - Drug Profile 143
etoposide phosphate reformulation - Drug Profile 144
Drug Targeting EZH2-EED - Drug Profile 145
THR-53 - Drug Profile 146
Laulimalide Derivatives - Drug Profile 147
Cyt-PLAT - Drug Profile 148
Small-Cell Lung Cancer Therapeutics – Drug Profile Updates 149
Small-Cell Lung Cancer Therapeutics – Discontinued Products 184
Small-Cell Lung Cancer Therapeutics - Dormant Products 185
Small-Cell Lung Cancer – Product Development Milestones 187
Featured News & Press Releases 187

Appendix 195
Methodology 195
Coverage 195
Secondary Research 195
Primary Research 195
Expert Panel Validation 195
Contact Us 196
Disclaimer 196

List of Table


Number of Products Under Development for Small-Cell Lung Cancer, H2 2013 13
Products under Development for Small-Cell Lung Cancer Comparative Analysis, H2 2013 14
Number of Products under Development by Companies, H2 2013 16
Number of Products under Development by Companies, H2 2013 (Contd..1) 17
Number of Products under Development by Companies, H2 2013 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2013 19
Comparative Analysis by Late Stage Development, H2 2013 20
Comparative Analysis by Mid Clinical Stage Development, H2 2013 21
Comparative Analysis by Early Clinical Stage Development, H2 2013 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 23
Products under Development by Companies, H2 2013 24
Products under Development by Companies, H2 2013 (Contd..1) 25
Products under Development by Companies, H2 2013 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2013 27
Bristol-Myers Squibb Company, H2 2013 28
Boehringer Ingelheim GmbH, H2 2013 29
Sanofi-Aventis, H2 2013 31
Eli Lilly and Company, H2 2013 32
Merck & Co., Inc., H2 2013 33
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 34
ZIOPHARM Oncology, Inc., H2 2013 35
ImmunoGen, Inc., H2 2013 37
Nippon Kayaku Co., Ltd., H2 2013 38
Alchemia Limited, H2 2013 43
Hana Biosciences, Inc., H2 2013 44
ImmunoCellular Therapeutics, Ltd., H2 2013 45
Critical Outcome Technologies Inc., H2 2013 46
CytRx Corporation, H2 2013 47
Synta Pharmaceuticals Corp., H2 2013 48
MabVax Therapeutics, Inc., H2 2013 49
Supratek Pharma Inc., H2 2013 50
TheRyte Ltd., H2 2013 51
Celator Pharmaceuticals, Inc., H2 2013 52
Cerulean Pharma, Inc., H2 2013 53
OncoMed Pharmaceuticals, Inc., H2 2013 54
Five Prime Therapeutics, Inc., H2 2013 55
Merrimack Pharmaceuticals, Inc., H2 2013 56
Neotropix, Inc., H2 2013 57
MolMed S.p.A., H2 2013 58
Innogene Kalbiotech Pte Ltd., H2 2013 59
Laboratorios Farmaceuticos ROVI, S.A., H2 2013 60
Mycenax Biotech Inc., H2 2013 61
Polaris Group, H2 2013 62
CellAct Pharma GmbH, H2 2013 63
Assessment by Monotherapy Products, H2 2013 64
Assessment by Combination Products, H2 2013 65
Assessment by Stage and Route of Administration, H2 2013 67
Assessment by Stage and Molecule Type, H2 2013 70
Small-Cell Lung Cancer Therapeutics Drug Profile Updates 153
Small-Cell Lung Cancer Therapeutics Discontinued Products 188
Small-Cell Lung Cancer Therapeutics Dormant Products 189
Small-Cell Lung Cancer Therapeutics Dormant Products (Contd..1) 190

List of Chart


Number of Products under Development for Small-Cell Lung Cancer, H2 2013 13
Products under Development for Small-Cell Lung Cancer Comparative Analysis, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 19
Late Stage Products, H2 2013 20
Mid Clinical Stage Products, H2 2013 21
Early Clinical Stage Products, H2 2013 22
Discovery and Pre-Clinical Stage Products, H2 2013 23
Assessment by Monotherapy Products, H2 2013 64
Assessment by Combination Products, H2 2013 65
Assessment by Route of Administration, H2 2013 66
Assessment by Stage and Route of Administration, H2 2013 67
Assessment by Molecule Type, H2 2013 68
Assessment by Stage and Molecule Type, H2 2013 69

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *